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ABSTRACT
Background. Minimally invasive parathyroidectomy
(MIP) is the preferred approach to primary hyperparathy-
roidism (PHPT) when a single adenoma can be localized
preoperatively. The added value of intraoperative para-
thyroid hormone (IOPTH) monitoring remains debated
because its ability to prevent failed parathyroidectomy due
to unrecognized multiple gland disease (MGD) must be
balanced against assay-related costs. We used a decision
tree and cost analysis model to examine IOPTH monitoring
in localized PHPT.
Methods. Literature review identiﬁed 17 studies involving
4,280 unique patients, permitting estimation of base case
costs and probabilities. Sensitivity analyses were per-
formed to evaluate the uncertainty of the assumptions
associated with IOPTH monitoring and surgical outcomes.
IOPTH cost, MGD rate, and reoperation cost were varied
to evaluate potential cost savings from IOPTH.
Results. The base case assumption was that in well-
localized PHPT, IOPTH monitoring would increase the
success rate of MIP from 96.3 to 98.8%. The cost of
IOPTH varied with operating room time used. IOPTH
reduced overall treatment costs only when total assay-
related costs fell below $110 per case. Inaccurate locali-
zation and high reoperation cost both independently
increased the value of IOPTH monitoring. The IOPTH
strategy was cost saving when the rate of unrecognized
MGD exceeded 6% or if the cost of reoperation exceeded
$12,000 (compared with initial MIP cost of $3733). Setting
the positive predictive value of IOPTH at 100% and
reducing the false-negative rate to 0% did not substantially
alter these ﬁndings.
Conclusions. Institution-speciﬁc factors inﬂuence the
value of IOPTH. In this model, IOPTH increased the cure
rate marginally while incurring approximately 4% addi-
tional cost.
Minimally invasive parathyroidectomy (MIP), also
known as focused parathyroidectomy or limited parathy-
roid exploration, is known to yield long-term cure rates
equivalent to those achieved with conventional bilateral
neck exploration.
1,2 MIP requires relatively accurate pre-
operative localization, however. In most expert centers,
MIP is now the preferred surgical approach to sporadic
primary hyperparathyroidism (PHPT) when a single ade-
noma can be localized preoperatively.
3 The fraction of
patients who undergo MIP has increased over time and
varies across institutions, ranging from 57 to 92% cur-
rently.
4 This ﬁgure largely hinges on the accuracy of
preoperative localization studies, most commonly techne-
tium 99 m sestamibi scanning and ultrasound.
Many centers use intraoperative parathyroid hormone
(IOPTH) monitoring as an adjunct to MIP. Although some
experts consider it essential for success, others have ques-
tioned the added value that IOPTH monitoring brings when
disease is adequately preoperatively localized.
5 Drawbacks
associated with IOPTH use include the cost of the assay,
operating room (OR) time associated with waiting for
results, and the potential for misleading the surgeon
into performing unnecessary further exploration (false
negatives).
6 Published single-institution reports show a
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cess rates for initial MIP when IOPTH monitoring is used:
95–97.5% without IOPTH vs. 97–99% with IOPTH.
7–11 For
patients with positive localization studies, the purpose of
IOPTH monitoring is to unmask cases of multiple gland
parathyroid disease (MGD) not recognized on imaging. In
cases where the IOPTH decreases immediately after single-
glandresection,theneedtoexaminetheothernormalglands
is obviated.
The addition of IOPTH monitoring to MIP increases the
cost of a focused exploration. Whether this cost is justiﬁed
by the potential prevention of failed operations remains
debated. In addressing this topic, several questions must be
considered: (1) What is the added cost of IOPTH moni-
toring? (2) What is the rate of unrecognized MGD in
patients with positive localization? (3) What are the per-
formance characteristics of IOPTH monitoring? (4) What
is the cost of reoperation after initial surgery fails?
In this study, we use a decision tree and cost analysis to
examine the inﬂuence of the aforementioned factors on the
cost of IOPTH monitoring in localized PHPT.
METHODS
Case Deﬁnition
We created a decision-tree model to analyze the cost of
IOPTH on the basis of the accuracy of preoperative
localization studies, the cost of reoperation, MGD rate, and
cost of IOPTH. A reference case scenario was created on
the basis of a hypothetical 60-year-old woman with bio-
chemically conﬁrmed asymptomatic PHPT and no prior
neck operations, who met the 2002 consensus criteria for
parathyroidectomy.
12 A literature review was conducted to
obtain estimates of the costs and probabilities used in the
model. We identiﬁed 17 studies involving 4,280 unique
patients. Sensitivity analyses were performed to evaluate
the uncertainty of the assumptions associated with IOPTH
monitoring and surgical outcomes.
Decision Model
Decision analysis software (TreeAge Pro 2008; TreeAge
Software, Williamstown, MA) was used to construct a
decision model for the treatment of the reference case. The
complete decision tree is shown in Fig. 1. Different treat-
ment pathways were created for the two alternatives: ﬁrst,
MIP without the use of IOPTH, and second, MIP with the
use of IOPTH. The selected probabilities are shown in
Table 1. The hypothetical patient was assumed to be a
surgical candidate with no history of neck surgery and that
parathyroidectomy could be safely performed through a
cervical incision (i.e., no sternotomy, thoracotomy, or
thoracoscopy required for ectopic glands). The cure rate for
initial parathyroidectomy without IOPTH was assigned a
probability of 96.3%. Relevant long-term complications of
surgery included permanent recurrent laryngeal nerve
damage and hypoparathyroidism. The risk of long-term
complications resulting from initial parathyroid surgery
was set at 1–2%. The risks of temporary recurrent laryngeal
nerve damage or hypoparathyroidism were not factored
into the model. Failed initial parathyroidectomy led to one
reoperation. Costs related to medical management were not
considered given our assumption of an asymptomatic
patient.
As shown in Fig. 1, we analyzed decision pathways
where IOPTH is or is not used. We used the operating
characteristics of IOPTH to determine the added value of
IOPTH monitoring in patients with adequate preoperative
localization of parathyroid adenomas. Studies analyzed
generally used the Miami criterion to predict cure versus
the need for continued exploration (IOPTH decrease C50%
from the highest of either preincision or preexcision level
at 10 min after gland excision).
13 The costs and probabil-
ities were based on distributions of values determined from
reviewing the literature (Table 1).
Costs
Direct medical costs of surgery, complications, and
IOPTH were estimated by using reported Medicare charge
and reimbursement data, and are reported in Table 2 in
2005 U.S. dollars. We used a third-party payer perspective
(Medicare diagnosis-related groups) to calculate costs
(Table 2). Costs that were outside the health care system
(e.g., transportation and lost-productivity costs) were not
included in the analysis. Only costs that differed among the
two treatment strategies were included. We calculated the
cost of OR time via the following formula, derived from
Medicare reimbursement for anesthesia: cost = [6 ? (time
in minutes/15) * 17.78] (Table 3).
Sensitivity Analysis
The reference case scenario was tested by using sensi-
tivity analysis to identify the uncertainty of the results.
14
Each variable in the model was tested independently across
a range of possible values to determine the impact of dif-
ferent assumptions on the cost results. Key assumptions
were tested with the use of sensitivity analysis, in which
the effects of simultaneously changing multiple variables
were analyzed.
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In our model, the base case assumption was that IOPTH
improves the operative success rate from 96.3 to 98.8%. At
baseline conditions, the IOPTH strategy increased the
treatment cost by 3.8%. IOPTH was cost saving when
assay-related costs were less than $110 per case (Fig. 2), or
when the cost of reoperation exceeded $12,000 (Fig. 3).
The probability of failure to cure PHPT by single-gland
parathyroidectomy without IOPTH monitoring is a surro-
gate for the rate of unrecognized MGD in patients with
well-localized disease. If the probability of cure without
IOPTH monitoring is[94%, under base case IOPTH and
PHPT patient with
adequate
localization
No IOPTH
monitoring
IOPTH
monitoring
Adequate fall,
end procedure
Inadequate fall,
bilateral exploration
Cure
Persistence
No significant complications
Significant complications
No significant complications
Significant complications
Cure
Persistence
No significant complications
Significant complications
No significant complications
Significant complications
Cure
Persistence
No significant complications
Significant complications
No significant complications
Significant complications
FIG. 1 Complete decision model for management of localized primary hyperparathyroidism with or without intraoperative parathyroid
hormone monitoring
TABLE 1 Probabilities used in
decision-tree analysis and
supporting references
IOPTH intraoperative
parathyroid hormone, PHPT
primary hyperparathyroidism
Description Probability
used
References
Probability of clinically important complication
after multigland exploration
0.02
10,11,32,33
Probability of clinically important complication
after single-gland exploration
0.01
10,11
Probability of cure with IOPTH monitoring 0.988
8,11,15,17,20,25,27,29,34–37
Probability of cure without IOPTH monitoring 0.963
7–9,15,18,19,21,25,28,36–38
Probability that IOPTH decreases in localized PHPT 0.96
7,8,11,15,17,20,26,27,34–36,39
TABLE 2 Costs by Medicare diagnosis-related group used in deci-
sion-tree analysis
Description Cost ($)
Cost of clinically important complications 5166.67
Cost of IOPTH 266.24
Cost of multigland surgery 4433.33
Cost of reoperation 5710.89
Cost of single-gland parathyroidectomy 3733.33
IOPTH intraoperative parathyroid hormone
TABLE 3 Estimated operating room time by type of procedure
performed
Time
(min)
Cost
($)
a
Procedure
45 160.02 MIP without IOPTH
75 195.58 MIP with IOPTH, adequate decrease, end
procedure
b
105 231.14 MIP with IOPTH, inadequate decrease, convert
to BNE
MIP minimally invasive parathyroidectomy, IOPTH intraoperative
parathyroid hormone monitoring, BNE bilateral neck exploration
a Cost = [6 ? (time in minutes/15) * 17.78]
b IOPTH decrease of C50% from the highest of either preincision or
preexcision level at 10 min after gland excision
IOPTH Cost Analysis 681reoperation costs, the use of IOPTH will increase treatment
costs (Fig. 4). If the probability of cure without IOPTH
monitoring is\94%, the use of IOPTH will reduce treat-
ment costs. Two-way sensitivity analyses also yielded
threshold values for cost savings of IOPTH on the basis of
test-related costs and cost of reoperation, according to the
probability of cure without IOPTH monitoring (Figs. 5, 6).
As the probability of cure without IOPTH decreases to
\90%, IOPTH monitoring becomes the dominant strategy
in both analyses. Conversely, as the probability of cure
without IOPTH exceeds 98%, it is never cost saving to use
IOPTH monitoring, even when test-related costs are as low
as $25 and the cost of reoperation is $50,000.
We also performed sensitivity analysis on the perfor-
mance characteristics of IOPTH monitoring. In our model,
the rates of false-positive and false-negative IOPTH results
are represented by the probability that IOPTH decreases
when a single localized gland is removed. Raising the
probability that IOPTH decreases to 100% simultaneously
optimizes the positive predictive value of IOPTH and
eliminates false-negative results that would prompt
unnecessary continued exploration. In two-way sensitivity
analysis, the use of an ideally performing IOPTH test is
cost saving when the probability of cure without IOPTH
monitoring decreases below 94% (Fig. 7). Less-than-per-
fect IOPTH test performance requires a lower probability
of cure without IOPTH monitoring in order for IOPTH to
become cost saving.
DISCUSSION
The true cost of IOPTH monitoring must be assessed on
a hospital population basis as represented by the following
equation
6:
Population cost of IOPTH monitoring
¼ Population cost of IOPTH monitoring in every patient
þCost of unnecessary continued explorations
 Cost savings from avoided failures
In other words, although a relatively small fraction of
patients with localized disease truly beneﬁt from the use of
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FIG. 2 One-way sensitivity analysis of cost of intraoperative para-
thyroid hormone (IOPTH). IOPTH monitoring becomes cost saving
when test-related costs fall below $110. This value considers both the
cost of the test and the cost of operating room time spent waiting for
results
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FIG. 3 One-way sensitivity analysis of reoperation cost. Intraoper-
ative parathyroid hormone (IOPTH) monitoring becomes cost-saving
when the reoperation cost increases above $12,000. The difference in
the slopes of the two lines reﬂects the marginal improvement in
success rate of initial surgery associated with IOPTH monitoring in
the model
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FIG. 4 One-way sensitivity analysis of probability of cure without
intraoperative parathyroid hormone (IOPTH) monitoring. IOPTH
monitoring becomes cost saving when the probability of cure without
IOPTH monitoring decreases below 94%. In the model, this
probability relates inversely with the prevalence of undetected
multiple gland disease among patients with positive localization
studies
682 L. F. Morris et al.IOPTH, the cost of IOPTH monitoring is borne broadly.
Institutions that routinely use IOPTH monitoring might fall
into three general categories regarding the justiﬁcation for
this added cost: (1) centers that have high rates of unrec-
ognized MGD among patients with positive localization,
either as a result of a high overall prevalence of MGD or
relatively low accuracy of preoperative localization stud-
ies; (2) centers that leverage IOPTH monitoring to begin all
cases as limited explorations, irrespective of imaging
results; and (3) centers that aim to cure 100% of patients,
regardless of cost.
8,11,15–19 Detractors primarily focus on
the limited ‘‘added value’’ of IOPTH monitoring, arguing
that a 1% improvement in success rates with IOPTH
monitoring is not merited by the high cost of the test, as
well as the false-negative rate of 1.2–9.8% that leads to
unnecessary continued explorations.
5,10,20,21
It is increasingly evident that the contribution of IOPTH
monitoring varies inversely with the accuracy of localiza-
tion studies. Even the strongest advocates of IOPTH
monitoring admit to its marginal beneﬁt in patients with
deﬁnitive preoperative localization.
22 The ostensible pur-
pose of IOPTH monitoring in localized PHPT is to unmask
unrecognized MGD; however, the ability of the test to
successfully serve this function is not certain. Perversely,
the accuracy of IOPTH is reduced in the presence of MGD,
prompting some experts to comment that ‘‘the test works
best when it is needed least.’’
23,24
Our literature review of predominantly single-institution
studies revealed wide variation in several critical factors
that were likely to inﬂuence the surgeon’s decision to use
IOPTH. The most striking of these was the prevalence of
unrecognized MGD in patients with positively localized
disease, which ranged from 1.6 to 22%.
5,7,10,15–19,25–29 This
variation prompted us to surmise that divided opinions
regarding the value of IOPTH monitoring rest not on
dogma but rather arise as rational adaptations to disparate
institution-speciﬁc factors. Our analyses are thus inclusive
of wide ranges in MGD rate, IOPTH cost, and reoperation
cost.
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FIG. 5 Two-way sensitivity analysis of cost of intraoperative
parathyroid hormone (IOPTH) and probability of cure without
IOPTH monitoring. The reference case values, derived from Medicare
diagnosis-related groups and literature review, are shown. When all
other assumptions in the model are held constant, this analysis permits
cost assessment of IOPTH monitoring among institutions with
different published rates of undetected multiple gland disease
(MGD). When the MGD rate is 22% (Cleveland (16)), IOPTH
monitoring is always cost saving, irrespective of test-related costs.
When the MGD rate is 10% (Madison (8)), IOPTH monitoring
becomes cost saving as test-related costs fall below $440. When the
MGD rate is 2% (Sydney (5)), IOPTH monitoring is never cost saving
50
40
30
20
10
0.70 1.00
Probability of Cure without IOPTH Monitoring
0.95 0.80 0.75 0.90 0.85
Not using IOPTH monitoring
is cost-saving on this
side of the threshold line
IOPTH monitoring
is cost-saving on this
side of the threshold line
Cost of
Reoperation
($ Thousands)
Reference case value = $5710.89, 0.965
FIG. 6 Two-way sensitivity analysis of cost of reoperation and
probability of cure without intraoperative parathyroid hormone
(IOPTH) monitoring. The y-axis is inclusive of an approximately
ninefold error in reoperation cost. The reference case values are
shown
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FIG. 7 Two-way sensitivity analysis of probability that intraopera-
tive parathyroid hormone (IOPTH) decreases and probability of cure
without IOPTH monitoring. Raising the probability that IOPTH
decreases to 100% optimizes test performance. The reference case
values are shown
IOPTH Cost Analysis 683True costs of IOPTH vary and are difﬁcult to quantify.
Costs associated with IOPTH include cost of the assay, the
machine, and a dedicated technician, with three to ﬁve
assays per case. Most assays take 8–16 min to deliver a
result. Because the 10-min postexcision parathyroid hor-
mone level is the one most typically relied on, total waiting
time in the OR can approach 30 min. From the third-party
payer cost perspective used in our model, the marginal cost
of 1 min of OR time is $1.19, a value that we based on the
following Medicare formula, which includes only the cost
of anesthesia: Cost = [6 ? (time in minutes/15) * 17.78].
The IOPTH cost used in the model ($266.24) considers this
plus an expected payment of $56.76 for each of four assays
used per case. In contrast to these ﬁgures, the cost of OR
time in a recent surgical workﬂow study was $15.05 per
minute.
30 Incorporation of such real-world time costs
would work considerably against IOPTH monitoring in
decision analysis.
Because our threshold value for IOPTH cost was $110,
well under $266.24, IOPTH monitoring did not reduce
treatment costs under base case assumptions. However, the
IOPTH cost only comprised a small fraction of the total
cost of care per patient, ranging from a base of 4% to a
maximum of 20% increase in cost when IOPTH cost was
raised to $1000.
Examination of Figs. 5, 6 and 7 reveals conditions when
IOPTH monitoring is the cost-saving strategy. However, in
most cited reports from expert centers, the probability of
cure without IOPTH monitoring is 95% or more among
localized cases, conﬁning these institutions to the far right-
hand side of the two-way sensitivity analyses. Along the
95% vertical, not using IOPTH is cost saving when the
remaining assumptions are held constant.
We found that IOPTH monitoring became cost saving
when the cost of reoperation exceeded $12,000, which is
more than three times the cost of initial MIP ($3733).
Although the cost of reoperation is certainly higher than
that of the initial operation in published reports, the mag-
nitude of the difference is well under threefold, in keeping
with our own experience.
31 This suggests that a strategy
permissive of a small number of failed initial operations,
rather than one aiming for an initial cure rate of 100%,
would be most cost conscious.
Several recent publications have described the applica-
tion of second-tier localization studies in sestamibi-
negative patients, most notably parathyroid-protocol com-
puted tomographic scans. Our analyses suggest that adding
such an examination would only be cost saving if the
probability of cure without computed tomography were
unacceptably low. In practice, this scenario would likely
occur in institutions where the performance of sestamibi
scanning lay below the median found in our literature
review.
Because our study did not include quality of life indi-
cators, we are unable to comment on the cost-effectiveness
of the strategies shown. Our analyses only indicate cir-
cumstances when IOPTH monitoring can be expected to
negatively or positively affect the cost of care. Moreover,
our study modeled cases with positive localization and
ﬁndings are not generalizable to the overall population of
patients with PHPT. We conclude that in the management
of localized PHPT, the cost impact of IOPTH monitoring
depends on institution-speciﬁc factors, most importantly
the prevalence of unrecognized MGD. The marginally
improved cure rate achieved with IOPTH monitoring was
offset by an increased cost of care per patient.
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